Navigation Links
Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
Date:3/16/2008

Phase I/II data showed that Enhanze Technology(TM) enabled subcutaneous administration of a monthly dose of GAMMAGARD LIQUID in patients with

Primary Immunodeficiency

PHILADELPHIA, March 16 /PRNewswire-FirstCall/ -- Baxter International Inc. (NYSE: BAX) today announced the preliminary results of a Phase I/II clinical trial, in which subcutaneous infusion (under the skin) of GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] (IGIV) with Enhanze(TM) Technology enabled administration of a full monthly dose via a single site to patients with primary immunodeficiency (PID). The results were presented at the annual meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in Philadelphia, PA.

GAMMAGARD LIQUID is approved for intravenous administration, which due to large infusion volumes of the therapy needing to be delivered, can take several hours once a month at a doctor's office or hospital. By contrast, subcutaneous administration of IGIV has been limited by the inability of the tissue to absorb large volumes of injected drugs, creating the need to administer the therapy in smaller, weekly doses and through multiple injection sites. Subcutaneous administration of GAMMAGARD LIQUID with Enhanze Technology via a single site could allow patients to administer a sufficient dose of IGIV once monthly at home.

In the Phase I/II trial, 10 of the 11 patients studied received monthly doses of subcutaneously administered GAMMAGARD LIQUID with Enhanze Technology of 25.5 to 61.2 grams (255 to 612 mL) in a single site. All patients in the trial received the therapy at infusion rates between 120 mL/hr to 300 mL/hr, similar to infusion rates for intravenous administration. The average bioav
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
2. U.S. Department of Health and Human Services Completes Funding of 2006 Contract Award to CSCs DVC and Baxter
3. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
4. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
7. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
8. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
9. Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections
10. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
11. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC ... guide with accompanying instrumentation to place and insert the ... the soft tissue (e.g. ligament) repair or reconstruction as ... heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
(Date:1/14/2014)... 2014   Oligomerix, Inc. , a privately held company ... disease (AD) and related neurodegenerative disorders, announced today the ... NY as of January 15, 2014 and ... York Medical College. Oligomerix, which is focused ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ), Eli ... Inc. (Nasdaq: ALKS ) today announced that the ... response letter regarding the New Drug Application (NDA) for BYDUREON™ ... complete response letter the FDA requested a thorough QT (tQT) ...
... , Matt Perkins, chief technology officer and senior vice ... provider of ZigBee-based real-time location solutions ( RTLS ) ... real-time location and condition sensing and ZigBee -based ... and beyond at the 2010 Mobile Health Expo.  WHAT: ...
Cached Medicine Technology:Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™ 2Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™ 3Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™ 4Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™ 5Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™ 6Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™ 7Awarepoint to Present 'ZigBee-based Wireless Sensor Networks for Use in Acute Care Hospitals and Beyond' at Mobile Health Expo Speaker Session 2Awarepoint to Present 'ZigBee-based Wireless Sensor Networks for Use in Acute Care Hospitals and Beyond' at Mobile Health Expo Speaker Session 3
(Date:4/17/2014)... Council scientists and their partners have found that their ... the transmission of multiple sexually transmitted infections (STIs) in ... simplex virus 2 (HSV-2), and human papillomavirus (HPV). The ... gel is effective against multiple strains of HIV, and ... all three viruses of at least eight hours prior ...
(Date:4/17/2014)... and alleviates muscle soreness after exercise, according to ... Illinois at Chicago. , The study, reported online ... of Physical Medicine and Rehabilitation , also showed ... had not exercised, suggesting that massage has benefits ... activity. , Improved circulation and relief of muscle ...
(Date:4/17/2014)... 94 per cent of Canadians surveyed said they would ... a specific number of genetic conditions, only 80 per ... screening that would sequence their newborns, genomes.,Most newborns in ... first day or two of life in which a ... and tested for about five to 54 conditions, depending ...
(Date:4/17/2014)... its status as the leading weapon against the deadly ... with new research indicating it simply needs to be ... of the cheap anti-malarial drug chloroquine in treating and ... more than half a million people each year around ... developed resistance to chloroquine, but research carried out at ...
(Date:4/16/2014)... , PHOENIX, Ariz. April 15, 2014 The ... Arizona philanthropists at their annual Founders Dinner for their ... cancer. The event took place March 28 in Scottsdale. ... & Catherine Ivy Foundation, received TGen,s John S. McCain ...
Breaking Medicine News(10 mins):Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:Scientists find new way to fight malaria drug resistance 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... work better in protecting children from flu if they included ... Louis University research has found. "Adding a second influenza ... some of the guesswork out of strain selection and help ... M.D., lead investigator and director of the Center for Vaccine ...
... ... Wigix Inc.’s subsidiary, ddku.com, affording it an end to end marketing platform in China. ... Oakland, CA ... has acquired a Shanghai-based business process outsourcing company, Mag2U, to enhance DDKU’s growing internet ...
... diagnosis should consider genetic testing, experts say , TUESDAY, April ... age 55 who also have a genetic mutation that boosts ... cancer in the opposite breast than are women who don,t ... Risk increased fourfold for these women, who carry a mutation ...
... (Baltimore, MD) Today, the Interactive Autism Network ... project, announces results of the Grandparents of Children ... one-third of grandparents who participated were the first ... its launch in 2007, the IAN Project has ...
... April, 2010 The global nursing shortage is due in ... to a phenomenon known as nurse migration, where nurses leave ... International Council of Nurses (ICN) and the Honor Society of ... Foundation, will conduct the Global Summit on Nurse Faculty Migrationa ...
... Attention-deficit/hyperactivity disorder (ADHD) is one of the most common ... ADHD are excessively restless, impulsive, and distractible and experience ... are a common theme for ADHD symptoms. These ... or a combination of the two. In ...
Cached Medicine News:Health News:Building a better flu vaccine: Add second strain of influenza B 2Health News:Wigix Acquires Mag2U, A Leading Business Process Outsourcing Company 2Health News:Wigix Acquires Mag2U, A Leading Business Process Outsourcing Company 3Health News:Gene Mutations Up Risk for Cancer in Opposite Breast 2Health News:Gene Mutations Up Risk for Cancer in Opposite Breast 3Health News:New survey finds grandparents play key role in lives of children with autism 2Health News:New survey finds grandparents play key role in lives of children with autism 3Health News:International summit seeks solutions to global shortage of nursing faculty 2Health News:Synergy between behavioral and pharmacologic interventions for ADHD 2
... single-lead principle has been applied to cardiac resynchronization ... which consists of the Tupos LV/A+ and the ... surgery and the risk of complications. The ICD ... via a single lead. The atrial input stage ...
... ICD cardiac resynchronization and ICD device offers ... The unit's RV only sensing provides no ... LV depolarizations, eliminating this cause of inappropriate ... LV separation for optimized hemodynamics. Proven PR ...
... The Medtronic InSync II Marquis ... and ICD therapy. Cardiac resynchronization benefits ... adapt pacing outputs to unique patient ... monitoring functions that help physicians manage ...
... Guidant's Contak Renewal 2 cardiac resynchronization ... therapy for the treatment of heart ... the right and left ventricles or ... contractions. The device provides ventricular tachyarrhythmia ...
Medicine Products: